These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 18989898

  • 1. Bromocriptine use and the risk of valvular heart disease.
    Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC.
    Mov Disord; 2009 Feb 15; 24(3):344-9. PubMed ID: 18989898
    [Abstract] [Full Text] [Related]

  • 2. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC, Anzouan-Kacou JB, Fauveau E, Bonnet AM, Lebrun-Vignes B, Girault C, Agid Y, Lechat P, Isnard R, Lacomblez L.
    Arch Neurol; 2007 Dec 15; 64(12):1721-6. PubMed ID: 18071034
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G, Ozekmekçi S, Koldas L, Sahin T, Erginöz E.
    Clin Neurol Neurosurg; 2007 May 15; 109(4):350-3. PubMed ID: 17307289
    [Abstract] [Full Text] [Related]

  • 6. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB, Reimold SC, O'Suilleabhain PE.
    Arch Neurol; 2007 Mar 15; 64(3):377-80. PubMed ID: 17353380
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A, Poewe W.
    Lancet Neurol; 2007 Sep 15; 6(9):826-9. PubMed ID: 17706566
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
    van Strater AC, Bax JJ, van Hilten JJ, Jukema JW.
    Ned Tijdschr Geneeskd; 2005 Apr 16; 149(16):891-4. PubMed ID: 15868996
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Yamamoto M, Uesugi T, Nakayama T.
    Neurology; 2006 Oct 10; 67(7):1225-9. PubMed ID: 17030757
    [Abstract] [Full Text] [Related]

  • 15. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG, García-Ruiz PJ, Sánchez-Pernaute R.
    Rev Neurol; 1997 Sep 10; 25(145):1343-5. PubMed ID: 9377286
    [Abstract] [Full Text] [Related]

  • 16. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
    Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E.
    Int J Clin Pract; 2008 Dec 10; 62(12):1864-9. PubMed ID: 18462372
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist.
    Watanabe H, Hirayama M, Noda A, Ito M, Atsuta N, Senda J, Kaga T, Yamada A, Katsuno M, Niwa T, Tanaka F, Sobue G.
    Neurology; 2009 Feb 17; 72(7):621-6. PubMed ID: 19221295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.